Type 1 Diabetes TrialNet
Study Participants Healthcare Professionals Researchers Locations Publications What is TrialNet? News and Events Get Screened! Home
TrialNet News and Events
Type 1 Diabetes - TrialNet e-news - Spring 2013



TrialNet launches new study aimed at preventing type 1 diabetes in those at risk
Encouraged by recent success at slowing down insulin loss in people newly diagnosed, TrialNet researchers will now use the same drug to try to prevent or delay type 1 diabetes in individuals at risk of developing the disease. This new clinical trial, using the drug CTLA4-Ig (Abatacept), is looking for relatives of people with type 1 diabetes to participate in ground breaking research. Go

TrialNet expands screening with online sign-up
TrialNet must screen more than 20,000 relatives of people with type 1 diabetes each year in order to find enough candidates to reach its research goals. That’s why we are always working to find ways to make screening more accessible.

Previously, those interested in screening would need to complete the consent process in person or by mail. With the introduction of online consent, there is now another option. Individuals can confirm their eligibility and complete the necessary consent documents online. When completed, TrialNet will send them a test kit to take to a local medical lab for a blood sample. The sample is sent to TrialNet’s central lab for testing. Results are reported in about 6 weeks. Go

Driving to Stop Diabetes…NASCAR’s Ryan Reed
Diagnosed 2 years ago with type 1 diabetes, NASCAR Nationwide driver Ryan Reed is still in the driver’s seat. Decked out with a new American Diabetes Association Drive to Stop Diabetes paint scheme, his No. 16 Ford Mustang will compete in several 2013 NASCAR races. Go



Pathway to Prevention Study (formerly the Natural History Study of the Development of Type 1 Diabetes):
Screening and observing relatives of people with type 1 diabetes to learn more about how the disease occurs.

Oral Insulin for Prevention of Type 1 Diabetes Study:
Testing whether a daily oral insulin capsule can prevent or delay type 1 diabetes in at-risk relatives of people with the disease.

Teplizumab (Anti-CD3) Prevention Study:
Testing whether the drug teplizumab can stop or slow down the autoimmune reaction that is destroying beta cells in people who are at high risk of developing type 1 diabetes.

Abatacept Prevention Study:
Testing whether abatacept, a medication that has shown promise in preserving insulin production in people newly diagnosed with type 1 diabetes, can help delay or prevent onset of the disease in people at increased risk.


Meet the Principal Investigator: William Russell, M.D.
Type 1 Diabetes TrialNet is proud to work with the world's leading experts in type 1 diabetes. In this issue, we feature TrialNet Principal Investigator William Russell, M.D., who is also chair of the Abatacept Prevention Protocol. Dr. Russell, Cornelius Vanderbilt Professor of Pediatrics and Professor of Cell and Developmental Biology, is the Director of the Division of Pediatric Endocrinology and Diabetes at Vanderbilt University School of Medicine. Go

Taking part in research gives Florida family “safety net”
Adam and Dani Bello of Jupiter, FL, learned about TrialNet screening at the annual Children With Diabetes conference in Orlando in 2007. That was the year their son Max was diagnosed with type 1 diabetes at age 5.

A year later, the Bellos took their two other sons to be screened. That’s when they learned that their then five-year-old son, Grant, tested positive for antibodies that signal an increased risk for type 1 diabetes. “We very quickly transitioned from being upset to deciding to do whatever it took,” says Adam. “We met with Dr. Schatz and the TrialNet staff at the University of Florida. They told us about the Oral Insulin Study. They helped make the decision easy.” Go

Diabetes Camp—Connecting families and research
The Hendersons of Keller, Texas, are just one of the thousands of families who have benefited from TrialNet screenings at diabetes camp. In August 2012, Robin Henderson was volunteering at Camp Aurora, when she learned about TrialNet screening. She immediately arranged for her three children to get screened. “Because I have type 1 diabetes, it was a no-brainer for me,” she said. “If you can be prepared for it, why wouldn’t you?” Go


JDRF Walks…Making great strides for TrialNet research

Last year, TrialNet screened 1,372 relatives of people with type 1 diabetes at 83 JDRF Walks. JDRF Walk to Cure Diabetes draws people together in a healthy activity for a worthy goal, raising money to improve the lives of all people affected by type 1 diabetes. Funds help to accelerate progress on the most promising opportunities for curing, better treating, and preventing the disease. The walk is fun for families and builds camaraderie among company employees. To find a walk near you, visit walk.jdrf.org.

TrialNet risk screening available virtually anywhere

TrialNet risk screening is available at more than 200 locations throughout North America or anywhere in the United States via mail. You can find a TrialNet screening location by using our online referral tool. To request a test kit by mail, go to www.Pathway2Prevention.org and complete the informed consent process, or contact one of our clinical centers listed here. The test kit can be taken to a local medical lab to collect a blood sample for analysis by TrialNet’s lab. Risk screening is available at no charge to those who are:

  • age 45 and younger who have a parent, sibling or child with type 1 diabetes, or
  • age 20 and younger who have a niece, nephew, aunt, uncle, grandparent, half-sibling, or cousin with type 1 diabetes.

Facebook Visit us on Facebook You Tube TrialNet YouTube Channel Twitter Follow us on Twitter

Join TrialNet in the fight against type 1 diabetes!

Here's how YOU can help:

  • If you have a relative with type 1 diabetes, find out if you are eligible for screening; if you are, get involved and get your family screened
  • Forward TrialNet E-News to family members and friends who might be interested
  • Tell your TrialNet Story by creating a video for TrialNet’s YouTube channel
  • Share this information on your MySpace or Facebook page
  • Follow TrialNet on Facebook and Twitter